Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2011-08-04 Regulatory Filings
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about new loan agreements (PNC Loan Agreement and Equipment Loan Agreement), financial covenants, and a reference to a press release announcing quarterly financial results. The document does not contain full financial statements or comprehensive financial analysis itself but rather announces material definitive agreements and financial obligations. It also includes a press release as an exhibit but does not contain the full earnings release text within the main body. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories like Annual Report, Earnings Release, or Capital/Financing Update. Although it discusses financing agreements, the primary purpose is to report material definitive agreements and related financial obligations, typical of an 8-K filing under the Exchange Act, which fits under Regulatory Filings (RNS).
2011-08-04 English
4 Filing
Director's Dealing
2011-07-29 English
4 Filing
Director's Dealing
2011-07-29 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the departure of a senior executive (Kyle Keese) from the company, including details about severance and termination. This fits the category of announcements related to changes in the company's board of directors or senior management. The document does not contain financial statements or detailed financial data, so it is not an annual or interim report. It is not a proxy statement, earnings release, or other categories. Therefore, the best classification is Board/Management Information (MANG). The document length is short and focused on management change, confirming this classification with high confidence.
2011-07-12 English
4 Filing
Director's Dealing
2011-06-09 English
4 Filing
Director's Dealing
2011-06-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.